Renske ten Ham is an assistant professor at the UMC Utrecht in the Netherlands and specializes in health economics & health technology assessment (HTA) of regenerative medicines, including gene and cell-based therapies. Trained as a pharmacist and with an MSc in HTA, she holds a PhD in Drug Innovation titled: “Development, market authorization and market access of gene- and cell-based therapies”.

Over the years Renske conducted research at the University of California, San Francisco (UCSF) and the Center of Health Economics at the University of York and collaborated with many more. She also spent time at the Dutch Medicines Evaluation Board (CBG-MEB) and Dutch National Health Care Institute (Zorginstituut Nederland). She is the recipient of the CHE Research Fellowship and an NWO VENI Laureate.

At the Julius Center Renske is lead of the Regenerative Medicines (RM) team within the Health Economic Evaluation-group. She strives to increase translation of RM and (academic) gene and cell-based therapies towards implementation in healthcare services. In doing so her research focusses on payment models, development cost, (early) economic evaluations and funding/business models. She aims to contribute to better understanding of the fit between innovative therapies and existing development frameworks. This is not only relevant for RM but also for future biomedical innovations.

Current:

• Co-chair & founder -  Regulatory Science Netwerk Netherlands (RSNN) - Special Interest Group Advanced Therapies
• Chair-elect -  ISPOR Special Interest Group Precision Medicine and Advanced Therapies
• Co-chair - PDA Advanced Therapy Medicinal Products Conference  to be held June 2025, Gotenburg
• Committee member - KWF Proof of Concept Program
• Committee member - KWF PIPELINE Program
• Member - Young Science in Transition
• Member - The Professional Society for Health Economics and Outcomes Research (ISPOR) 
• Member - Dutch Association of Medical Technology Assessment (NVTAG)
• Member - Dutch Association for Health Economics (VGE)

Past:

• Co-chair - PDA Advanced Therapy Medicinal Products Conference  held in Amsterdam [2024]
• Chair -  ISPOR Special Interest Group Precision Medicine and Advanced Therapies [2023 - 2024]
• Member - Access Equity Think Tank, European Haemophilia Consortium (EHC) [2023 - 2024]
• Participant - Research Career Development Talent Program, UMC Utrecht [2022 - 2023]
• Member - Scientific Program Planning Committee PDA Advanced Therapy Medicinal Products Conference held in Brussels, Belgium [2022]
• Board member NVTAG (Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg) [2017 - 2020]
• President young-NVTAG (Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg [2017 - 2020]
• Founder & president ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Student Chapter at Utrecht University. [2014 - 2016]

Gene therapies, Cell-based therapies, Advanced Therapy Medicinal Product, Regulatory Science, Policy Research, Health Technology Assessment, Health Economics, (Early) Economic Evaluations, Methodology, Business Models, Development Cost, organoids, Organ-o-a-chip, Medical Innovations, Pharmaceuticals, Medicinal Products

NWO VENI Laureate 2023/2024

• The Veni is an annually awarded, personal scientific grant and part of the NWO Talent Program.
• With this grant I will develop new methods using Bayesian statistics to reduce uncertainty in cost-effectiveness analyses to better inform reimbursement decisions using gene therapies for spinal muscular atrophy and hemophilia B as case studies.

CHE Research Fellowship Award 2023/2024

• By Centre for Health Economics (CHE) of the University of York, UK
• Research Fellowship to visit CHE in 2024 for three months to work on Innovative payment mechanisms for gene therapies: moving from theory to practice using the case of haemophillia.

Greiner Award 2020&2021

• Award for the best thesis defended in 2020&2021
• By Dutch Association of Gene & Cell Therapy (NVGCT)

Publication featured as Trends Editors Pick 2020

• Journal: Trends in Pharmacological Sciences
• Awarded publication: Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection.

Publication featured as  Editors Pick 2020

• Journal: Value in Health
• Awarded publication: A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature.

Best Scientific Poster 2019

• Conference: TOPRA Conference 2019
• Awarded poster: Challenges in Advanced Therapy Medicinal Product Development